Modern approaches to therapeutic oligonucleotide manufacturing
Top Cited Papers
- 12 April 2024
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6692) , eadl4015
Abstract
Therapeutic oligonucleotides are a powerful drug modality with the potential to treat many diseases. The rapidly growing number of therapies that have been approved and that are in advanced clinical trials will place unprecedented demands on our capacity to manufacture oligonucleotides at scale. Existing methods based on solid-phase phosphoramidite chemistry are limited by their scalability and sustainability, and new approaches are urgently needed to deliver the multiton quantities of oligonucleotides that are required for therapeutic applications. The chemistry community has risen to the challenge by rethinking strategies for oligonucleotide production. Advances in chemical synthesis, biocatalysis, and process engineering technologies are leading to increasingly efficient and selective routes to oligonucleotide sequences. We review these developments, along with remaining challenges and opportunities for innovations that will allow the sustainable manufacture of diverse oligonucleotide products.Keywords
This publication has 99 references indexed in Scilit:
- Liquid‐Phase Oligonucleotide Synthesis: Past, Present, and Future PredictionsCurrent Protocols in Nucleic Acid Chemistry, 2019
- Liquid-Phase Synthesis of Oligonucleotides2018
- Synthesis of Trinucleotide Building Blocks in Solution and on Solid PhaseCurrent Protocols in Nucleic Acid Chemistry, 2018
- Inotersen: First Global ApprovalDrugs, 2018
- AJIPHASE®: A Highly Efficient Synthetic Method for One‐Pot Peptide Elongation in the Solution Phase by an Fmoc StrategyAngewandte Chemie International Edition, 2017
- Liquid‐Phase Synthesis of 2′‐Methyl‐RNA on a Homostar Support through Organic‐Solvent NanofiltrationChemistry – A European Journal, 2015
- Mipomersen Sodium: First Global ApprovalDrugs, 2013
- First "Antisense" Drug Will Treat CMV RetinitisJAMA, 1998
- A stereoselective synthesis of dinucleotide phosphorothioates, using chiral phosphoramidites as intermediatesTetrahedron Letters, 1996
- The antiviral activity of thiophosphate-substituted polyribonucleotides in vitro and in vivoVirology, 1970